Prevention of Thrombocytopenia and Thrombosis in Heparin-Induced Thrombocytopenia (HIT) Using Deglycosylated KKO: A Novel Therapeutic for HIT? Prevention of Thrombocytopenia and Thrombosis in Heparin-Induced Thrombocytopenia (HIT) Using Deglycosylated KKO: A Novel Therapeutic for HIT?

Prevention of Thrombocytopenia and Thrombosis in Heparin-Induced Thrombocytopenia (HIT) Using Deglycosylated KKO: A Novel Therapeutic for HIT?

On Tuesday, July 20, 2021, Amrita Sarkar, Ph.D., of the University of Pennsylvania and Children's Hospital of Philadelphia in Philadelphia presented research about heparin-induced thrombocytopenia (HIT) and a potential new therapeutic.
Read more
Oral Pazopanib Results in Durable Hemostasis in Patients with Severe Bleeding and RBC Transfusion-dependent Hereditary Hemorrhagic Telangiectasia Oral Pazopanib Results in Durable Hemostasis in Patients with Severe Bleeding and RBC Transfusion-dependent Hereditary Hemorrhagic Telangiectasia

Oral Pazopanib Results in Durable Hemostasis in Patients with Severe Bleeding and RBC Transfusion-dependent Hereditary Hemorrhagic Telangiectasia

On Tuesday, July 20, 2021, Hanny Al-Samkari, M.D., of Massachusetts General Hospital in Boston presented results on oral pazopanib for severe hereditary hemorrhagic telangiectasia (HHT)-associated bleeding.

Read more
RSS